+

SK1182004A3 - Perorálne antidiabetické činidlá - Google Patents

Perorálne antidiabetické činidlá Download PDF

Info

Publication number
SK1182004A3
SK1182004A3 SK118-2004A SK1182004A SK1182004A3 SK 1182004 A3 SK1182004 A3 SK 1182004A3 SK 1182004 A SK1182004 A SK 1182004A SK 1182004 A3 SK1182004 A3 SK 1182004A3
Authority
SK
Slovakia
Prior art keywords
phenyl
methyl
ethoxy
propionic acid
pyrrol
Prior art date
Application number
SK118-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Christopher Franklin Bigge
Alexander James Bridges
Agustin Casimiro-Garcia
Stephen Alan Fakhoury
Helen Tsenwhei Lee
Jessica Elizabeth Reed
Robert Philipp Schaum
Kevin Matthew Schlosser
Karen Elaine Sexton
Hairong Zhou
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of SK1182004A3 publication Critical patent/SK1182004A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
SK118-2004A 2001-08-29 2002-07-15 Perorálne antidiabetické činidlá SK1182004A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31572801P 2001-08-29 2001-08-29
PCT/IB2002/002843 WO2003018553A1 (fr) 2001-08-29 2002-07-15 Agents antidiabetiques oraux

Publications (1)

Publication Number Publication Date
SK1182004A3 true SK1182004A3 (sk) 2005-03-04

Family

ID=23225787

Family Applications (1)

Application Number Title Priority Date Filing Date
SK118-2004A SK1182004A3 (sk) 2001-08-29 2002-07-15 Perorálne antidiabetické činidlá

Country Status (35)

Country Link
EP (2) EP1423363B1 (fr)
JP (1) JP2005504778A (fr)
KR (1) KR20040044515A (fr)
CN (1) CN1558897A (fr)
AP (1) AP2002002616A0 (fr)
AR (1) AR036301A1 (fr)
AT (1) ATE323674T1 (fr)
BG (1) BG108597A (fr)
BR (1) BR0212069A (fr)
CA (1) CA2458621A1 (fr)
CZ (1) CZ2004272A3 (fr)
DE (1) DE60210784T2 (fr)
EA (1) EA200400140A1 (fr)
EC (1) ECSP044999A (fr)
EE (1) EE200400075A (fr)
ES (1) ES2260456T3 (fr)
GT (1) GT200200175A (fr)
HN (1) HN2002000242A (fr)
HR (1) HRP20040164A2 (fr)
HU (1) HUP0401620A2 (fr)
IL (1) IL159886A0 (fr)
IS (1) IS7114A (fr)
MA (1) MA27135A1 (fr)
MX (1) MXPA04001968A (fr)
NO (1) NO20040881L (fr)
OA (1) OA12653A (fr)
PA (1) PA8553701A1 (fr)
PE (1) PE20030563A1 (fr)
PL (1) PL369569A1 (fr)
SK (1) SK1182004A3 (fr)
SV (1) SV2003001213A (fr)
TN (1) TNSN04038A1 (fr)
UY (1) UY27424A1 (fr)
WO (1) WO2003018553A1 (fr)
ZA (1) ZA200400374B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
PA8594401A1 (es) * 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
EP1620088A4 (fr) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp Derives d'acide indole acetique et leur utilisation en tant qu'agents pharmaceutiques
JP2007516171A (ja) * 2003-06-27 2007-06-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｎ２−アルキル化１，２，３−トリアゾールの調製
BRPI0412236A (pt) * 2003-07-02 2006-09-12 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos
US7202266B2 (en) * 2003-07-17 2007-04-10 Plexxikon, Inc. PPAR active compounds
MXPA06004642A (es) 2003-11-05 2006-06-27 Hoffmann La Roche Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar).
WO2005056522A2 (fr) 2003-12-04 2005-06-23 National Health Research Institutes Composes indoles
FR2863610B1 (fr) * 2003-12-11 2006-01-20 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
ES2285554T3 (es) 2003-12-11 2007-11-16 GALDERMA RESEARCH & DEVELOPMENT Nuevos compuestos que son moduladores de receptores de tipo ppar y su uso en composiciones cosmeticas o farmaceuticas.
EP1697339A1 (fr) 2003-12-25 2006-09-06 Takeda Pharmaceutical Company Limited Derives d'acide 3-(4-benzyloxyphenyl) propanoique
EP1725546B1 (fr) * 2004-03-09 2008-10-08 F.Hoffmann-La Roche Ag Derives de pyrazolyl-indolyle utilises comme activateurs de ppar
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
CA2649735C (fr) 2006-04-18 2016-02-09 Nippon Chemiphar Co., Ltd. Agent d'activation du recepteur d active par les proliferateurs des peroxisomes
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
SI2277874T1 (sl) 2008-04-15 2019-01-31 Nippon Chemiphar Co., Ltd. Aktivator za peroksisomski proliferator-aktiviran receptor
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
WO2013139341A1 (fr) * 2012-03-20 2013-09-26 Syddansk Universitet Modulateurs de récepteurs gpr120
WO2013185766A1 (fr) * 2012-06-15 2013-12-19 Syddansk Universitet Modulateurs du récepteur gpr120

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3275999A (en) * 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
ATE286032T1 (de) * 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
WO2000023425A1 (fr) * 1998-10-21 2000-04-27 Novo Nordisk A/S Nouveaux composes, preparation et utilisation correspondantes
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
MXPA01010916A (es) * 1999-04-28 2002-06-21 Reddy Research Foundation Heterociclos biciclicos sustituidos, procedimiento para su preparacion y su uso como agentes contra la obesidad y como agentes hipocolesterolemicos.
DE60008763T2 (de) * 1999-09-08 2005-02-10 Glaxo Group Ltd., Greenford Oxazol ppar antagonisten

Also Published As

Publication number Publication date
EP1577305A1 (fr) 2005-09-21
IS7114A (is) 2004-01-15
HRP20040164A2 (en) 2004-10-31
PE20030563A1 (es) 2003-06-23
WO2003018553A8 (fr) 2004-04-08
UY27424A1 (es) 2003-03-31
WO2003018553A1 (fr) 2003-03-06
ECSP044999A (es) 2004-04-28
HN2002000242A (es) 2002-12-12
NO20040881L (no) 2004-04-19
GT200200175A (es) 2003-05-23
CZ2004272A3 (cs) 2005-02-16
EP1423363A1 (fr) 2004-06-02
EP1423363B1 (fr) 2006-04-19
CA2458621A1 (fr) 2003-03-06
BG108597A (bg) 2005-03-31
PL369569A1 (en) 2005-05-02
CN1558897A (zh) 2004-12-29
IL159886A0 (en) 2004-06-20
TNSN04038A1 (fr) 2006-06-01
AR036301A1 (es) 2004-08-25
OA12653A (en) 2006-06-16
DE60210784T2 (de) 2006-11-02
SV2003001213A (es) 2003-03-18
AP2002002616A0 (en) 2002-09-30
ES2260456T3 (es) 2006-11-01
JP2005504778A (ja) 2005-02-17
ZA200400374B (en) 2005-03-30
PA8553701A1 (es) 2003-07-28
MXPA04001968A (es) 2004-06-07
MA27135A1 (fr) 2005-01-03
HUP0401620A2 (hu) 2004-11-29
EE200400075A (et) 2004-08-16
BR0212069A (pt) 2004-07-20
DE60210784D1 (de) 2006-05-24
ATE323674T1 (de) 2006-05-15
KR20040044515A (ko) 2004-05-28
EA200400140A1 (ru) 2004-08-26

Similar Documents

Publication Publication Date Title
SK1182004A3 (sk) Perorálne antidiabetické činidlá
JP3255930B2 (ja) ＰＰＡＲ―γに対するアゴニスト活性を有する置換４―ヒドロキシフェニルアルカン酸誘導体
AU2013341945B2 (en) GPR40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient
JP5232771B2 (ja) Ｈｄｌ−ｃの増加、ｌｄｌ−ｃの低下およびコレステロールの低下のために使用されるｐｐａｒ−デルタ作用物質としてのベンゾアゼピン−オキシ−酢酸誘導体
CN113195441A (zh) 雄激素受体调节剂及其使用方法
WO2004106276A1 (fr) Compose cyclique condense
EA011010B1 (ru) Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
WO2003057674A1 (fr) Composes derives de 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyle destines au traitement des maladies associees au recepteur 5-ht2c
KR20080056288A (ko) Ｐｐａｒ 조절제로서의 화합물 및 조성물
JP2011251974A (ja) 新規ヘテロアリール誘導体
JP2017519025A (ja) チオフェン−２−イル−ピリジン−２−イル−１ｈ−ピラゾール−４−カルボン酸誘導体、および可溶性グアニル酸シクラーゼ活性化剤としてのその使用
KR20080059635A (ko) Ｐｐａｒ 조절제로서의 화합물 및 조성물
JPWO2006075638A1 (ja) 新規ヘテロアリール誘導体
KR20220141331A (ko) P2x3 조정제
HUP0300857A2 (hu) Peroxiszóma proliferátor aktivált agonisták
WO2014199164A1 (fr) Composés hétéroaromatiques diaryle substitués
KR20080065674A (ko) 신규한 인돌 함유 베타 효능제, 이의 제조 방법 및약제로서의 이의 용도
US20030171377A1 (en) Antidiabetic agents
CN113677659B (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
CN113677666A (zh) 作为类法尼醇x受体调节剂的经取代的双环化合物
AU2002317434A1 (en) Oral antidiabetic agents
JP2006036730A (ja) 新規ピロール誘導体
KR20070030791A (ko) Ｐｐａｒ 조절제로서의 화합물 및 조성물

Legal Events

Date Code Title Description
FC9A Refused patent application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载